JP2011516422A5 - - Google Patents

Download PDF

Info

Publication number
JP2011516422A5
JP2011516422A5 JP2011502090A JP2011502090A JP2011516422A5 JP 2011516422 A5 JP2011516422 A5 JP 2011516422A5 JP 2011502090 A JP2011502090 A JP 2011502090A JP 2011502090 A JP2011502090 A JP 2011502090A JP 2011516422 A5 JP2011516422 A5 JP 2011516422A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
eosinophilic
composition according
human
humanized anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011502090A
Other languages
English (en)
Japanese (ja)
Other versions
JP5917143B2 (ja
JP2011516422A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/038509 external-priority patent/WO2009120927A2/en
Publication of JP2011516422A publication Critical patent/JP2011516422A/ja
Publication of JP2011516422A5 publication Critical patent/JP2011516422A5/ja
Application granted granted Critical
Publication of JP5917143B2 publication Critical patent/JP5917143B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011502090A 2008-03-28 2009-03-27 処置方法 Active JP5917143B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4036308P 2008-03-28 2008-03-28
US61/040,363 2008-03-28
PCT/US2009/038509 WO2009120927A2 (en) 2008-03-28 2009-03-27 Methods of treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014158170A Division JP6069267B2 (ja) 2008-03-28 2014-08-01 処置方法

Publications (3)

Publication Number Publication Date
JP2011516422A JP2011516422A (ja) 2011-05-26
JP2011516422A5 true JP2011516422A5 (OSRAM) 2016-02-04
JP5917143B2 JP5917143B2 (ja) 2016-05-11

Family

ID=41114741

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011502090A Active JP5917143B2 (ja) 2008-03-28 2009-03-27 処置方法
JP2014158170A Active JP6069267B2 (ja) 2008-03-28 2014-08-01 処置方法
JP2016214438A Active JP6457463B2 (ja) 2008-03-28 2016-11-01 処置方法
JP2018238018A Pending JP2019065029A (ja) 2008-03-28 2018-12-20 処置方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014158170A Active JP6069267B2 (ja) 2008-03-28 2014-08-01 処置方法
JP2016214438A Active JP6457463B2 (ja) 2008-03-28 2016-11-01 処置方法
JP2018238018A Pending JP2019065029A (ja) 2008-03-28 2018-12-20 処置方法

Country Status (14)

Country Link
US (3) US9834600B2 (OSRAM)
EP (1) EP2274009B1 (OSRAM)
JP (4) JP5917143B2 (OSRAM)
KR (1) KR20100134702A (OSRAM)
CN (1) CN102026660A (OSRAM)
AU (1) AU2009228163B2 (OSRAM)
BR (1) BRPI0910854A2 (OSRAM)
CA (1) CA2719786A1 (OSRAM)
EA (1) EA201071137A1 (OSRAM)
ES (1) ES2441945T3 (OSRAM)
IL (1) IL208354A0 (OSRAM)
MX (1) MX2010010667A (OSRAM)
WO (1) WO2009120927A2 (OSRAM)
ZA (1) ZA201006648B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010521496A (ja) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク. キラル精製置換ベンゾチアゾールジアミンの合成
KR20100134702A (ko) * 2008-03-28 2010-12-23 글락소스미스클라인 엘엘씨 치료 방법
EP2334185A4 (en) 2008-08-19 2011-09-21 Knopp Neurosciences Inc COMPOSITIONS AND METHODS FOR USE OF (R) -PRAMIPEXOL
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
SMT202100119T1 (it) 2013-07-12 2021-05-07 Knopp Biosciences Llc Trattamento dei livelli elevati di eosinofili e/o basofili
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
EP3033081B1 (en) 2013-08-13 2021-05-12 Knopp Biosciences LLC Compositions and methods for treating chronic urticaria
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
KR102495432B1 (ko) 2014-09-08 2023-02-03 세파론 엘엘씨 중등증 내지 중증의 호산성 천식을 치료하기 위한 레슬리주맙의 용도
CN116327923A (zh) 2015-08-24 2023-06-27 葛兰素史密斯克莱知识产权(第2 号)有限公司 生物医药组合物
CN117018190A (zh) 2017-05-26 2023-11-10 葛兰素史密斯克莱知识产权发展有限公司 生物制药组合物和相关方法
MX2023001140A (es) * 2020-08-05 2023-05-18 Areteia Therapeutics Inc Uso del dexpramipexol para el tratamiento de asma moderado a grave.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800397D0 (en) * 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
US5096704A (en) * 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
IL92180A (en) 1988-11-03 1997-04-15 Schering Corp Pharmaceutical composition for preventing or reducing eosinophilia
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
DK0654085T3 (da) 1992-01-23 1997-09-22 Merck Patent Gmbh Monomere og dimere antistof-fragment-fusionsproteiner
WO1993016184A1 (en) 1992-02-06 1993-08-19 Schering Corporation Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
JPH06141885A (ja) 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
WO1995014040A1 (en) 1993-11-19 1995-05-26 Baylor College Of Medicine Monoclonal antibodies specific for human interleukin-5
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US6129913A (en) 1994-12-23 2000-10-10 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7399837B2 (en) * 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US6248723B1 (en) * 1997-06-10 2001-06-19 National Jewish Medical And Research Center Method for treatment of inflammatory disease
HUP0004170A3 (en) * 1997-10-22 2001-12-28 Ponikau Jens Rochester Methods and materials for treating and preventing inflammation ofmucosal tissue
WO2001012646A1 (en) 1999-08-19 2001-02-22 Smithkline Beecham Corporation Sialoadhesin factor-1 agonist and antagonist antibodies
US20030017169A1 (en) * 2000-12-29 2003-01-23 Sidney Pestka Controlled release systems for polymers
SI1527100T1 (sl) * 2002-03-29 2009-12-31 Schering Corp Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo
US7339507B1 (en) * 2006-09-13 2008-03-04 Jiun-In Guo Device for video decoding
EP2111237B1 (en) * 2006-12-11 2015-03-18 BRACCO IMAGING S.p.A. Fibrin-binding peptides and conjugates thereof
US20100086554A1 (en) 2007-04-30 2010-04-08 Smithkline Beecham Corporation Methods for administering anti-il-5 antibodies
US20090035216A1 (en) * 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
KR20100134702A (ko) 2008-03-28 2010-12-23 글락소스미스클라인 엘엘씨 치료 방법
US8926631B2 (en) 2010-08-06 2015-01-06 MoMelan Technologies, Inc. Methods for preparing a skin graft without culturing or use of biologics
DK2672986T3 (da) 2011-02-09 2020-06-08 Glaxosmithkline Llc Frysetørrede formuleringer

Similar Documents

Publication Publication Date Title
JP2011516422A5 (OSRAM)
JP2014240408A5 (OSRAM)
Dakhama et al. Virus-specific IgE enhances airway responsiveness on reinfection with respiratory syncytial virus in newborn mice
JP2012046518A5 (OSRAM)
EP2433650A3 (en) Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
JP2013538553A5 (OSRAM)
JP2014502968A5 (OSRAM)
JP2014506321A5 (OSRAM)
TW200630346A (en) Pyrimidines as prostaglandin D2 receptor antagonists
JP2011511072A5 (OSRAM)
WO2008050329A3 (en) Novel sirnas and methods of use thereof
JP2011507891A5 (OSRAM)
JP2015529225A5 (OSRAM)
JP2020517696A5 (OSRAM)
JP2014530226A5 (OSRAM)
JP2013543501A5 (OSRAM)
CN101031305A (zh) 类风湿性关节炎的预防和/或治疗药物
RU2010132581A (ru) Способы терапии заболеваний легких
JP2018505882A5 (OSRAM)
JP2016512817A5 (OSRAM)
RU2010126598A (ru) Применение человеческого антитела, способного нейтрализовать вирус гепатита в, для профилактики или лечения инфекции вирусом гепатита в
Cho et al. Clinical characteristics of angioedema with eosinophilia
Eskian et al. Monoclonal antibodies for treatment of eosinophilic esophagitis
JP2011513310A5 (OSRAM)
JP2013528649A5 (OSRAM)